Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment.

• Publication year

  2016

• Venue

  Journal of Cachexia, Sarcopenia and Muscle

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcsm.12126PMID 27386169PMCID 4929828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

  2016cited by this paper
• Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

  2016cited by this paper
• Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

  2015cited by this paper
• Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015

  2015cited by this paper
• Cancer cachexia: understanding the molecular basis

  2014cited by this paper
• The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

  2013cited by this paper
• Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.

  2013cited by this paper
• Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia.

  2013cited by this paper
• Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial.

  2013cited by this paper
• Disrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease

  2013cited by this paper
• L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial

  2012cited by this paper
• The Role of Thalidomide and Placebo for the Treatment of Cancer-Related Anorexia-Cachexia Symptoms: Results of a Double-Blind Placebo-Controlled Randomized Study

  2012cited by this paper
• Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

  2012cited by this paper
• β- adrenergic agonists: substances with anabolic effect in animals for meat production

  2012cited by this paper
• The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

  2011cited by this paper
• Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference

  2010cited by this paper
• Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle

  2010cited by this paper
• A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

  2008cited by this paper
• Cachexia: a new definition.

  2008cited by this paper
• A Randomized, Controlled, Double-Blind Trial of s-Pindolol in Irritable Bowel Syndrome (IBS): 1045

  2007cited by this paper
• Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults?

  2007cited by this paper
• The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers

  2006cited by this paper
• Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study.

  2006cited by this paper
• Six minute walk test.

  2005cited by this paper
• The Six-Minute Walk Test

  2003cited by this paper
• International Symposium on Supportive Care in Cancer

  2001cited by this paper
• A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission.

  1994cited by this paper
• Pindolol: A New β-Adrenoceptor Antagonist with Partial Agonist Activity

  1983cited by this paper
• Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity.

  1983cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• Multimodal Therapeutic Strategies for the Management of Sarcopenia and Frailty in Chronic Obstructive Pulmonary Disease: A Narrative Review

  2026cites this paper
• Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions

  2026cites this paper
• Neuromuscular Junction as a Molecular Target in Sarcopenia: Mechanisms, Therapeutic Strategies, and Future Directions.

  2026cites this paper
• Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer

  2026cites this paper
• Cancer cachexia: molecular basis and therapeutic advances

  2026cites this paper
• A comparison of inflammatory markers’ potential to predict weight loss in advanced cancer: a prospective observational study

  2025cites this paper
• Role of diet, physical activity and new drugs in the primary management of cancer cachexia in gastrointestinal tumors – a comprehensive review

  2025cites this paper
• Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.

  2025cites this paper
• Cancer Cachexia: Causes and Therapeutic Strategies

  2025cites this paper
• Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series

  2025cites this paper
• Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions

  2025cites this paper
• Prevalence of Cachexia and Outcomes in Patients With Chronic Diseases: A National Database Analysis of 5 484 103 Hospitalisations

  2025cites this paper
• Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update

  2025cites this paper
• Current perspectives on sarcopenia: diagnosis and therapeutic approaches

  2025cites this paper
• New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies

  2025cites this paper
• Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer

  2025cites this paper
• Association of an impaired GH-IGF-I axis with cardiac wasting in patients with advanced cancer

  2024cites this paper
• Integrating Traditional Chinese Medicine in the management of cancer-associated cachexia: a comprehensive review of current research and future prospects

  2024cites this paper
• Cancer cachexia: multilevel metabolic dysfunction

  2024cites this paper
• Neurobiology of cancer: Adrenergic signaling and drug repurposing.

  2024cites this paper
• Ponsegromab for the Treatment of Cancer Cachexia.

  2024cites this paper
• Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis

  2024cites this paper
• CT-derived body composition and differential association with age, TNM stage and systemic inflammation in patients with colon cancer

  2024cites this paper
• Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature.

  2024cites this paper
• Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series

  2024cites this paper
• Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions

  2024cites this paper
• Adipose tissue rearrangement in cancer cachexia: The involvement of β3-adrenergic receptor associated pathways.

  2024cites this paper
• Therapy-naïve malignancy causes cardiovascular disease: A state-of-the-art cardio-oncology perspective.

  2024cites this paper
• The Current Landscape of Pharmacotherapies for Sarcopenia

  2024cites this paper
• Sarcopenia in Lung Cancer: A Narrative Review

  2023cites this paper
• Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis—Pathogenesis, Implications and Therapeutic Opportunities

  2023cites this paper
• Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia.

  2023cites this paper
• Effect of muscle mass, androgens, and glucocorticoids on health outcomes

  2023cites this paper
• Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series

  2023cites this paper
• The pathophysiology of cancer‐mediated cardiac cachexia and novel treatment strategies: A narrative review

  2023cites this paper
• Muscle wasting: emerging pathways and potential drug targets.

  2023cites this paper
• Update on the treatment of cancer cachexia.

  2023cites this paper
• Current and investigational medications for the treatment of sarcopenia.

  2023cites this paper
• Cancer cachexia: molecular mechanisms and treatment strategies

  2023cites this paper
• Pharmacotherapeutic options for cancer cachexia: emerging drugs and recent approvals

  2023cites this paper
• Effects of S‐pindolol in mouse pancreatic and lung cancer cachexia models

  2023cites this paper
• Abnormal lipid metabolism in cancer-associated cachexia and potential therapy strategy

  2023cites this paper
• Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer.

  2023cites this paper
• Thrombosis and cachexia in cancer: two partners in crime?

  2023cites this paper
• The small molecule ACM‐001 improves cardiac function in a rat model of severe cancer cachexia

  2023cites this paper
• Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

  2023cites this paper
• Managing Nutrition Impact Symptoms in Cancer Cachexia: A Case Series and Mini Review

  2022cites this paper
• An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia

  2022cites this paper
• Muscle Health

  2022cites this paper
• The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model

  2022cites this paper
• Review of the endocrine organ–like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma

  2022cites this paper
• Targeting cancer cachexia: Molecular mechanisms and clinical study

  2022cites this paper
• Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy

  2022cites this paper
• A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction

  2022cites this paper
• Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers - Ready for prime time?

  2022cites this paper
• Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review

  2022cites this paper
• Drugs for the Treatment of Muscle Atrophy

  2021cites this paper
• Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.

  2021cites this paper
• Cancer Cachexia

  2021cites this paper
• Does sarcopenia affect postoperative short- and long-term outcomes in patients with lung cancer?—a systematic review and meta-analysis

  2021cites this paper
• Acceptability, Compliance, and Safety of Non-small Cell Lung Cancer Cachectic Participants Continuing Compassionate Access in the ACCeRT Clinical Study

  2021cites this paper
• LncRNA DLEU1 Contributes to the Growth and Invasion of Colorectal Cancer via Targeting miR-320b/PRPS1

  2021cites this paper
• Exercise Therapy for Patients with Heart Failure: Focusing on the Pathophysiology of Skeletal Muscle

  2021cites this paper
• Cancer cachexia: molecular mechanism and pharmacological management.

  2021cites this paper
• Mediators and clinical treatment for cancer cachexia: a systematic review

  2021cites this paper
• MT‐102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia

  2020cites this paper
• Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

  2020cites this paper
• Beta-blockers, hypertension, and weight gain: the farmer, the chicken, and the egg.

  2020cites this paper
• How progressive cancer endangers the heart: an intriguing and underestimated problem

  2020cites this paper
• A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial

  2020cites this paper
• Updated protocol and guest participant results from the ACCeRT clinical study

  2020cites this paper
• Cancer Cachexia and Related Metabolic Dysfunction

  2020cites this paper
• The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility

  2020cites this paper
• Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials

  2020cites this paper
• Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients.

  2020cites this paper
• Cancer Cachexia: Definition, Staging, and Emerging Treatments

  2020cites this paper
• The clinical relevance and mechanism of skeletal muscle wasting.

  2020cites this paper
• lncRNA ZNF667‐AS1 (NR_036521.1) inhibits the progression of colorectal cancer via regulating ANK2/JAK2 expression

  2020cites this paper
• Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies.

  2020cites this paper
• Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science

  2020cites this paper
• Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

  2020cites this paper
• CMAR_A_261585 5597..5605

  2020cites this paper
• Muscle Wasting Diseases: Novel Targets and Treatments.

  2019cites this paper
• Preoperative Cachexia predicts poor outcomes in young rather than elderly gastric cancer patients: a prospective study

  2019cites this paper
• The Journal of Cachexia, Sarcopenia and Muscle in 2019

  2019cites this paper
• Assessing Cachexia Acutely after Autologous Stem Cell Transplant

  2019cites this paper
• The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma.

  2019cites this paper
• Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials

  2019influential citation
• Using human experience to identify drug repurposing opportunities: theory and practice

  2019cites this paper
• Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives

  2019influential citation
• Cachexia/Anorexia and Feeding Difficulties

  2019cites this paper
• The difference in referencing in Web of Science, Scopus, and Google Scholar

  2019cites this paper
• The Role of Tumor and Tumor Microenvironment on Breast Cancer-Associated Adipocyte Plasticity

  2019cites this paper
• Muscle derangement and alteration of the nutritional machinery in NSCLC.

  2019cites this paper
• The Journal of Cachexia, Sarcopenia and Muscle stays the front‐runner in geriatrics and gerontology

  2019cites this paper
• Body composition and sarcopenia: The next‐generation of personalized oncology and pharmacology?

  2019cites this paper
• Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients

  2019cites this paper
• Cancer cachexia: an orphan with a future

  2019cites this paper
• Impact of preoperative cachexia on postoperative length of stay in elderly patients with gastrointestinal cancer.

  2019cites this paper
• Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review

  2019cites this paper